Abstract 4364
Background
Glioblastoma (GBM) is characterized by invasion, heterogeneity and high angiogenesis, conferring a poor prognosis. The aim of our study was to assess serum proteins related to these hallmarks with potential prognostic value in GBM.
Methods
Serum samples from GBM patients (N = 57 pts) were collected before Stupp regimen. We defined as “LT survivors” (LTS) those pts above 36-months survival, and as “ST survivors” (STS) those below 6-months survival. In the discovery cohort (N = 25 pts), 4 pts were identified in each group. A pooled analysis from serum samples of each group was performed by a protein profiling platform based on antibody array technology. Expressed proteins were assessed for differential expression between the two groups. In silico validation by using data obtained from French glioma study at R2 was performed. In situ expression levels from selected proteins involved in tumor progression (TP), cell proliferation (CP), invasion (Inv) and cell death (CD) that significantly correlate (p < 0.05) with OS in gliomas were studied. ELISA analysis against an independent sample set from the validation cohort (n = 32 pts, LTS n = 4, STS n = 7) was used to verify expression levels of the target proteins.
Results
A total of 1000 proteins were analyzed by the array. 214 proteins showed differences in fluorescence intensity more than 10-fold between LTS vs STS. Among them, SMAD4, SMAD5, TWEAK, VEGFR2, WISP1, FGF21, NEUROD1, SFRP3, SFPR4 and Bax were selected since obtained the highest differences in fluorescence intensity and correlated with differential OS outcomes in silico. ELISA validation demonstrated SFRP3 to be upregulated in the STS group (media expression (pg/ml) STS=1849;LTS=1039) (p = 0.018). No statistically significant differences were observed in the expression levels for the other proteins between LTS and STS. In validation cohort, median overall survival according to SFRP3 expression (low/high) was 19.7 months (CI 95% 10.7-28.61) vs 9.42 months (CI 95% 3.11-15.72) respectively, although did not reach statistical significance (p = 0.073).
Conclusions
Higher circulating SFRP3 level has been associated with STS in GBM. Overexpression of serum SFPR3 in GBM may be a surrogate indicator of poorer prognosis. Further studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GEINO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract